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Lacosamide is a new-generation antiseizure medication that is approved for use as an adjunctive treatment and
monotherapy in focal epilepsy. Its use in generalized epilepsy, however, has not been adequately evaluated in
controlled trials.We report a 67-year-oldwomanwho experienced new-onsetmyoclonic seizures after initiation
of lacosamide. We presume that she had an undiagnosed generalized epilepsy syndrome, likely juvenile myo-
clonic epilepsy. Myoclonic seizures were not reported before introducing lacosamide and completely resolved
after lacosamide was discontinued. This suggests that lacosamide may have the potential to worsen myoclonus,
similar to what has been reportedwith another sodium channel agent, lamotrigine, in some individuals with ge-
netic generalized epilepsy (GGE).










Juvenilemyoclonic epilepsy (JME) comprises 2–10% of all epilepsies,
and more than 25% of genetic generalized epilepsy (GGE). Estimates of
frequency vary in different clinical settings and across regions and coun-
tries,whichmay be due to variations in diagnostic criteria [1]. Appropri-
ate treatment includes valproic acid (VPA), levetiracetam (LEV),
topiramate, zonisamide (ZNS), and lamotrigine (LTG) among others
[2]. Some antiseizure medications (ASMs) are also known to aggravate
JME, including sodium channel agents such as carbamazepine (CBZ),
phenytoin (PHT) [3], and oxcarbazepine [4]. Another sodium channel
blocker, LTG, is often used successfully in JME, although it can exacer-
bate myoclonus in some individuals [5].
Approximately 20% of individuals with JME continue to have sei-
zures on VPA, the most efficacious ASM for the syndrome [2]. Although
the indication for the majority of new-generation ASMs is in focal epi-
lepsy, there is interest in exploring their application in generalized epi-
lepsy. A case series of three individuals with refractory JME reported
benefit from lacosamide (LCM) without adverse reactions [6]. Here,
we report a case of de novomyoclonic seizures occurring after introduc-
ing LCM, which completely resolved with its discontinuation.
2. Case history
A 67-year-old right-handed woman has a history of generalized
tonic-clonic seizures that started at age 17, when she was sleep-
deprived. Her seizures were managed well with phenobarbital (PB)
until a decade prior to her presentation, when she had two break-
through generalized tonic-clonic (GTC) seizures. She was found to
have a left-sided subdural hemorrhage and was switched from PB to
VPA 1500 mg/day. This was later adjusted to VPA 2000 mg/day and
LEV 1000 mg/day was added. Later, VPA was replaced by LCM, given
fewer cognitive side effects in the setting of comorbid dementia. Shortly
after initiating treatment with LCM, she began experiencing myoclonic
jerks 3–4 days per week for 15 min after awakening. According to her
husband, these jerks consisted primarily of flexion at the trunk that
could cause her to fall. The primary neurologist noted that myoclonic
jerks also affected the upper extremities. On the morning prior to ad-
mission, she experienced repetitive myoclonic jerks of the entire body
for 1 min, which were followed by a generalized seizure, and the myoc-
lonus continued after the generalized seizure. Over the course of ap-
proximately fifty years, this was her fifth or sixth generalized seizure.
She had a past medical history of advanced dementia, subdural hemor-
rhage in 2004 that was surgically evacuated, hypertension, and asymp-
tomatic atrial fibrillation. Her family history was positive for epilepsy in
her mother and grandmother.
The patient's physical examination upon admission to the hospital
demonstrated confusion.Her general laboratory evaluationwas normal.
A CT brain taken on admission showed old left cerebellar and pontine la-
cunar strokes, and a subsequent MRI did not reveal mesial temporal
sclerosis. Previous EEG in 2004, by charted information, revealed “bursts
of generalized slowing and some sharp and slow waves”, consistent
with genetic generalized epilepsy. A later EEG in 2008 was entirely nor-
mal. An EEG after discharge in 2014 showed slowing of the posterior
background rhythm to 6–7 Hz and generalized, frontal-maximum
spike-and-slow waves occurring singly, at a frequency of once every
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10–15 min, with phase reversals over F3 and F4 (Fig. 1). In addition,
there were some asymmetric sharply-contoured waveforms occurring
on the right and left, independently. A follow-up EEG showedonly back-
ground slowing to 6–8 Hz.
The presentation of morning myoclonus followed by GTC seizure,
teenage history of seizure after sleep deprivation, family history, and
EEG findings were suggestive of generalized epilepsy, likely JME. Thus,
LCM was discontinued and ZNS was initiated at 300 mg per day. LEV
was increased to 1500 mg per day. A subsequent visit to the hospital,
less than a month later, verified that her myoclonus had completely
stopped upon discontinuation of LCM. An EEG three months after the
admission revealed complete resolution of the interictal epileptiform
discharges, with persistence of the background slowing.
3. Discussion
The diagnosis of JME in this individual was difficult because contin-
uous video-EEG was not performed to capture ictal episodes. According
to the International League Against Epilepsy definition of JME, interictal
and ictal EEG may be similar and show rapid, generalized, often irregu-
lar spike-waves and polyspike-waves [7]. Other abnormalities that may
be present in a random sampling of individuals with JME include frontal
(N8%) and temporal (~5%) spike/sharp waves [8]. Our patient's EEG in
2004, 10 years prior to her presentation, was consistent with general-
ized epilepsy. A subsequent EEG in 2008 was normal, and an EEG after
discharge from the hospital demonstrated generalized, frontalmaximal,
single spike-wave discharges, further supporting generalized epilepsy,
associated with myoclonic seizures. Another EEG from 2013 noted fre-
quent sharpwaves and occasional higher voltage spikes over the left su-
perior frontal and temporal areas. These focalities and the sharply
contoured waves from the 2014 EEG may have represented focal dis-
charges secondary to one of hermany comorbidities, including subdural
hemorrhage, multiple strokes, and advanced dementia. Alternatively,
focal discharges may represent effective inhibitory mechanisms that
successfully fragment generalized epileptiform discharges in JME [9].
Ultimately, focal EEGfindings can be seen in JME and should not exclude
JME as the etiology of an individual's epilepsy [8].
In the past, uncertainty about a diagnosis of JME in this individual
likely revolved around a lack of morning myoclonus. Treatment with
LCM unmasked her myoclonus and was followed by a GTC seizure.
Given this individual's dementia, it is also possible that earlier in her
life she had myoclonus but had forgotten it when later questioned.
To verify that this was a drug-related adverse event, the Naranjo
method was employed. It revealed that this was a “possible” adverse
drug reaction. In the future, when myoclonus is encountered with
LCM use, in order to establish this as a “probable” or “definite” reaction,
clinicians can decrease the dose of LCMprior to discontinuation, consid-
er readministration of LCM after cessation, obtain drug levels, and con-
firm myoclonus through direct visualization [10].
In consideration of this myoclonus exacerbation being peculiar to
LCMuse in IGE and JME, several points can be raised. A reviewof adverse
side effects of LCM does not include myoclonus [11]. Additionally, this
individual's myoclonus was unlikely to have been related to high or
toxic drug levels. LTG, for example, at toxic levels, can triggermyoclonus
even when a seizure history is not present [12]. This individual was
using a standard dose of LCM. As there were no other reported side ef-
fects, toxicity was unlikely. LCM's pharmacology may have also played
a role. Severalmedications that affect the voltage-gated sodium channel
may worsen seizures in generalized epilepsy. In particular, CBZ, OXC,
and PHT have been reported to worsen absence andmyoclonic seizures
in GGE. LTG can worsen myoclonic seizures in some individuals with
GGE. This does not occur too commonly to preclude the inclusion of
LTG as a first line treatment in JME [2]. Lastly, genetics can modulate
the response of subsets of syndromes tomedications. For example, indi-
viduals with the progressive myoclonic epilepsy, Unverricht-Lundborg
disease, appear to beparticularly susceptible toworsening ofmyoclonus
when treatedwith LTG [13]. Similarly, the complex genetics of JME,with
multiple chromosomes implicated and possibly with incomplete pene-
trance [14], may allow subsets of JME to be particularly vulnerable to
myoclonus when LCM is utilized. Thus, some individuals may respond
optimally to LCM [15], while others may experience adverse effects.
4. Conclusion
In summary, this individual's history, physical, and diagnostic infor-
mation strongly suggest generalized epilepsy, likely JME, with myoclo-
nus that was unmasked by LCM. This case suggests that LCM may
have the potential to exacerbate underlyingmyoclonus, and its explora-
tion as a treatment in generalized epilepsies should take into consider-
ation the possibility of seizure exacerbation.
Fig. 1. Frontal-maximum, generalized spike-wave discharges (asterisks). Note the phase reversals over F3 and F4, typical of generalized epilepsy.
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